Olmesartan Stada (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartan Stada, is an angiotensin II receptor blocker presented as a tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Olmesartan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxil is used to treat high blood pressure by blocking the renin‑angiotensin system.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: used as part of combination therapy to improve symptoms and outcomes. - Diabetic nephropathy: helps slow progression of kidney damage associated with diabetes.

Olmesartan medoxil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Back pain

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation - Bullous skin reactions

When prescribing Olmesartan Stada, clinicians should consider several safety aspects.

- Renal function monitoring: assess baseline creatinine and eGFR before initiation. - Electrolyte balance: check potassium levels periodically, especially if combined with potassium‑sparing diuretics. - Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity. - Concomitant NSAID use: may blunt antihypertensive effect and increase renal risk. - Elderly patients: start at lower dose and monitor for orthostatic symptoms. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan medoxil can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): risk of renal dysfunction, hyperkalemia, and hypotension. - Potassium‑supplement supplements: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may diminish blood‑pressure‑lowering effect and affect kidney function. - Diuretics (especially thiazides): can increase risk of electrolyte disturbances. - Lithium: may raise serum lithium levels, risking toxicity. - ACE inhibitors or other ARBs: combined use can lead to excessive hypotension and renal impairment.